Aztreonam

Restricted
C. diff Risk

Medium

Oral Bioavailability

NA

Approximate Cost

$160/day

Spectrum Of Activity

Dosing

2g IV q8h for severe infections

Health Canada Special Access Programme Authorization required - consider contacting clinical pharmacist for support

0 - 10 eGFR10 - 50 eGFR50+ eGFR2g IV q24h

Health Canada Special Access Programme Authorization required - consider contacting clinical pharmacist for support3-4g IV daily divided q8-12h2g IV q8h

0.5-2g IV load then 500mg IV q12h

2g IV load then 1g IV q6h

General Information

Common Usage

Therapy of gram negative infections including Pseudomonas, particularly in patients with penicillin and cephalosporin allergy or when there is no alternative susceptible agent.

Nebulized form used in cystic fibrosis patients.

Empiric therapy for febrile neutropenia.

Drug Monitoring

Monitor liver enzymes

Adverse Effects

  •  Elevated liver enzymes

  •  Cytopenias

  •  Eosinophilia

  •  Phlebitis at injection site

  •  Rash/allergy

  •  CNS toxicity

Major Interactions

No significant

Additional Information

Health Canada Special Access Programme Authorization required - consider contacting clinical pharmacist for support

Pharmacology

Antimicrobial class: Monobactam

Pregnancy category: B

Average serum half life: 2.0

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Moderate